Cancer Anorexia Market

Key Highlights:

• The current treatment regimen for cancer anorexia includes off-label therapies like progestagens (megestrol acetate and medroxyprogesterone acetate), corticosteroids and other rarely prescribed medications (NSAIDs, omega 3 fatty acids and dronabinol).
• Expected Launch of potential therapies, ART27.13 (Artelo Biosciences) and NGM120 (NGM Biopharmaceuticals), may increase the market size in the coming years, assisted by an increase in the incident population of cancer anorexia.
• The total Cancer Anorexia Market Size in the 7MM was approximately USD 310 million in 2023 and is expected to increase during the forecast period (2024–2034).
• The total number of Cancer Anorexia I in the 7MM was around 763,400 in 2023.
• Among the 7MM, the US accounted for the highest Cancer Anorexia Incident Cases in 2023.
• The occurrence of cancer anorexia is high, especially in patients with advanced cancer, this syndrome often remains underdiagnosed.

Request for unlocking the CAGR of the Cancer Anorexia Market

Factors Affecting Cancer Anorexia Market Growth

• Rising Prevalence of Cancer

The increasing global incidence of various cancers directly contributes to a higher number of patients experiencing cancer-related anorexia. This growth in patient population is a major driver of the market.

• Growing Awareness of Cancer-Associated Malnutrition

Healthcare professionals are becoming increasingly aware of the impact of anorexia on cancer patient outcomes. Early identification and management of cancer anorexia improve quality of life, boosting demand for effective therapies.

• Advancements in Therapeutic Options

Development of pharmacological interventions, appetite stimulants, and nutritional supplements specifically targeting cancer anorexia is driving market growth by offering improved symptom management.

• Aging Population

Older adults are at higher risk for both cancer and related complications such as anorexia. The expanding geriatric population globally increases the prevalence of cancer anorexia, enhancing market demand.

• Increased Focus on Supportive and Palliative Care

As cancer care shifts toward holistic approaches, there is growing emphasis on managing side effects and complications like anorexia. This focus supports the adoption of therapies and nutritional interventions.

• Rising Investment in Research and Clinical Trials

Ongoing clinical trials and research initiatives aimed at understanding the mechanisms of cancer anorexia and developing targeted therapies are stimulating market growth.

• Expansion of Healthcare Infrastructure in Emerging Markets

Improved oncology care facilities, better diagnostic capabilities, and enhanced patient support systems in emerging regions are increasing patient access to treatments, driving market expansion.

DelveInsight's “Cancer Anorexia – Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Cancer Anorexia, historical and forecasted epidemiology as well as the Cancer Anorexia market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Cancer Anorexia Treatment Market Report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Cancer Anorexia market size from 2020 to 2034. The report also covers current Cancer Anorexia treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Cancer Anorexia Treatment Market: Understanding

Anorexia is a common symptom in people with cancer and a component of the cancer anorexia-cachexia syndrome (CACS). CACS is a multifactorial syndrome characterized by loss of muscles, which cannot be fully reversed by conventional nutritional support, and a cluster of symptoms that include anorexia, early satiety, and weakness. The primary cause of the development of CACS in cancer patients is related to metabolic changes that take place in response to the host–tumor interaction. Secondary causes include factors that contribute to primary cachexia through reduced food intake. These factors can include difficulty in swallowing, depression, change in taste, nausea, and food aversion. 

Cancer-related anorexia remains one of the most troublesome clinical problems experienced by patients with cancer during and after therapy. In general, the condition’s presence is clinically diagnosed when cancer patients refer to any negative change of their appetite. However, more symptoms such as reduction of appetite, early satiety, changes in taste, changes in odor, depression, dysphagia, painful swallowing, assessment of meal size, assessment of taste and odor are essential to diagnose the condition.

Further details will be provided in the report…

Cancer Anorexia Treatment

Several pharmacological and nutritional approaches have been used for the treatment of cancer-related anorexia. Keeping in mind that both anorexia and metabolic disturbances are involved, the development of different therapeutic strategies has focused on two major factors, namely, improving appetite and neutralizing metabolic disturbances. The management of cancer-related anorexia and weight loss is targeted at particular aspects. Current pharmacological agents can be divided into three categories: orexigenic agents (appetite stimulants), anti-catabolic (anti-metabolic and anti-cytokine) agents, and anabolic agents (primarily hormonal). Progestagens (megestrol acetate and medroxyprogesterone acetate) are the first-line therapy for cancer anorexia and cachexia. They are highly effective in relieving the symptoms of cancer anorexia.

Cancer Anorexia Epidemiology

The Cancer Anorexia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by incident cases of Cancer Anorexia, incident cases of Anorexia by Cancer types in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034. 

• In 2023, the total incident cases of Cancer Anorexia were approximately 277,200 cases in the US, which is expected to grow during the forecast period.
• Amongst EU4 and the UK, Germany accounted for the highest number of Cancer Anorexia incident cases, while Spain accounted for the least incident cases.
• Among all cancer types, Lung cancer accounts for the highest incident cases of Anorexia, approximately 150,300 in the US.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Cancer Anorexia Prevalence

Cancer Anorexia Drug Chapters

The drug chapter segment of the Cancer Anorexia treatment market report encloses a detailed analysis of Cancer Anorexia emerging drugs of late-stage (Phase I and Phase II) Cancer Anorexia pipeline drugs. It also deep dives into the Cancer Anorexia pivotal clinical trials details, recent and expected market approvals, patent details, the latest Cancer Anorexia news, and recent deals and collaborations. 

Cancer Anorexia Marketed Drugs

• ADLUMIZ/EDOLMIZU: Helsinn Healthcare

ADLUMIZ (anamorelin HCl/ONO-7643/ANAM) is a selective, novel, orally active ghrelin receptor agonist. Ghrelin is an endogenous peptide primarily secreted by the stomach. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite, and metabolism. Anamorelin has shown effects in increasing body weight and muscle mass, as well as appetite in patients with cancer cachexia. In January 2021, EDOLMIZU was approved for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, or colorectal cancer in Japan. 

Cancer Anorexia Emerging Drugs

• ART27.13: Artelo Biosciences

ART27.13 (formerly known as NEO1940 and AZD1940) is a highly potent, peripherally restricted synthetic, dual G-Protein Coupled Receptor (GPCR) agonist believed to target peripheral CB1/CB2 receptors, which has the potential to increase appetite and food intake. Originally developed by AstraZeneca, ART27.13 has been in five Phase I clinical studies, including over 200 subjects, where it demonstrated a statistically significant and dose-dependent increase in body weight in healthy subjects. Currently it is is enrolling for Phase IIa and completed Phase I study in subjects with lower back pain that were otherwise healthy demonstrated statistically significant increase in body weight versus drug exposure.

• NGM120: NGM Biopharmaceuticals

NGM120 is a first-in-class antagonistic antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling for the potential treatment of cancer and cancer anorexia/cachexia syndrome (CACS). In preclinical studies of NGM120, it has been demonstrated that blocking the interaction between GFRAL and GDF15 is able to both reduce tumor-associated weight loss and slow tumor growth and could potentially provide a novel treatment for CACS and cancer. Following the successful completion of a Phase I safety, tolerability, and pharmacokinetics study of NGM120 in healthy adult subjects in 2019, the drug is currently in a Phase Ia/Ib study.

Note: Detailed emerging therapies assessment will be provided in the final report.

Cancer Anorexia Drugs Market Report Insights

The landscape of cancer anorexia drug development encompasses several promising avenues, including ghrelin receptor agonists, dual G-protein coupled receptor (GPCR) agonists, and Growth Differentiation Factor 15 (GDF15) inhibitors. Ghrelin, an endogenous peptide primarily produced in the stomach, plays a vital role in regulating body weight, muscle mass, appetite, and metabolism upon binding to its receptor. Dual GPCR agonists, targeting peripheral CB1/CB2 receptors, show potential in enhancing appetite and food intake. NGM120 stands out as a first-in-class antagonistic antibody, binding to glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibiting GDF15 signaling. Preclinical studies of NGM120 have demonstrated its ability to mitigate tumor-associated weight loss and slow tumor growth by disrupting the interaction between GFRAL and GDF15. These findings suggest a promising avenue for treating cancer anorexia/cachexia syndrome (CACS) and associated cancer-related symptoms, offering a novel therapeutic approach to improve patient outcomes.

Cancer Anorexia Market Outlook

Currently, corticosteroids have been recommended in professional guidelines and have been associated with some improvement in appetite. Progestagens have also demonstrated an improved appetite in patients at various phases of care in multiple research studies and systematic reviews. Thus, steroid medication like dexamethasone and progesterone hormone-like medication like megestrol acetate are the most frequently used pharmacological drugs to stimulate appetite and improve weight. Additionally, as per PMR interviews, the prescription pattern of these medications vary in different regions, for instance, progestogens are considered as the first line treatment while corticosteroids are less frequently prescribed within the United States. The use of corticosteroids are limited in this region due to the high rate of adverse events associated with long term usage of this therapy along with the fact that the drug fails to increase the appetite after few months.

In addition to these therapies, there are certain rarely prescribed medications, namely, NSAIDs, Omega 3 fatty acids and Dronabinol. However, even after the presence and easy accessibility of these anti-anorectic pharmacological therapies, the patient compliance of these therapies are quiet low due to high rate of adverse events and high mortality rate in advanced anorectic cases.

At present, some Cancer Anorexia Companies have indulged themselves in initiating clinical trials that investigate new treatment options or studying how to use existing treatment options better. Key players such as Actimed Therapeutics  (ACM-001), Pfizer (PF 06946860), Artelo Biosciences (ART27.13) and several others are investigating their candidates for the management of Cancer Anorexias.

• The total Cancer Anorexia Market Size in the United States was approximately USD 131 million in 2023 and is projected to increase during the forecast period (2024–2034).
• Among EU4, Germany accounted for the maximum Cancer Anorexia market size in 2023, while Spain occupied the bottom of the ladder.
• In the Cancer Anorexia Market Sized by therapies , the highest revenue was generated by Progestagens in the United States in 2023.

Cancer Anorexia Drugs Uptake

This section focuses on the uptake rate of potential Cancer Anorexia drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Currently, there is only one high phase therapy, namely, anamorelin in the US and EU. Though the drug has recently been approved for treating cancer related cachexia in Japan, in January 2021, the factor that may threaten the success of this drug is the negative opinion of the Committee for Medicinal Products for Human Use (CHMP). Even as per PMR interviews, the drug has not demonstrated much potential in treating cancer related anorexia and thereby has not received positive feedback from wither FDA or EMA. As a results, the drug might face difficulty in gaining approval in Europe and the USA for cancer anorexia unless the drug is able to increase muscle strength, physical function, and prognosis in the clinical trials.

Besides anamorelin, the current pipeline possess two early phase therapies, namely ART27.13 and NGM120. Out of these two, Artelo Biosciences’ ART27.13 might have higher probability of success as the therapy has shown positive efficacy results in animal models so far. If approved, ART27.13 might acquire a decent market share in the forecast period due to its novel mechanism of action.

Further detailed analysis of emerging therapies drug uptake in the report…

Cancer Anorexia Pipeline Development Activities

The Cancer Anorexia therapeutics market report provides insights into therapeutic candidates in Phase I and II. It also analyzes key Cancer Anorexia Companies involved in developing targeted therapeutics. 

Pipeline Development Activities

The Cancer Anorexia therapeutics market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Cancer Anorexia emerging therapies. Companies likes NGM Biopharmecuticals and Artelo biosciences are actively engage in late-stage research and development efforts for Cancer Anorexia. Despite the relatively limited pipeline of potential drugs for this condition, the outlook for the therapeutics market is positive, with anticipated growth from 2024 to 2034. This optimism is fueled by ongoing advancements in understanding Cancer Anorexia biology, coupled with increased investment in innovative treatment approaches.

Latest KOL Views on Cancer Anorexia

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific Writers, Professors, and others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 18+ KOLs in the 7MM. Centers such as Sarcoma Oncology Center, Abramson Cancer Center, UC Davis Comprehensive Cancer Center in Sacramento etc. were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Cancer Anorexia market trends. 

Qualitative Analysis

We perform qualitative and Cancer Anorexia treatment market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. 

The analyst views analyze multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

In efficacy, the trial’s primary and secondary outcome measures are evaluated. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. 

Cancer Anorexia Treatment Market Access and Reimbursement 

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders. The payment models are based on clinical outcomes, annuity payments, and expanded risk pools.

The pharmaceutical companies must grant the following rebates: the general rebate of 7% of the manufacturer’s price will be paid by the pharmaceutical companies to the SHIs (Statutory health insurance funds) for all pharmaceuticals that are not subject to more specific price regulations. A special rebate of 10% of the manufacturer’s price is to be paid by the pharmaceutical companies to the SHIs for generics. Special rebates for vaccines are to be paid by the pharmaceutical companies to the SHIs and are calculated based on actual average prices in the four member states of the EU with gross national incomes. 

The Cancer Anorexiareport further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Cancer Anorexia Treatment Market Report Scope

• The Cancer Anorexia therapeutics market report covers a segment of key events, an executive summary, and a descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available and emerging therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will impact the current treatment landscape.
• A detailed review of the Cancer Anorexia therapeutics market, historical and forecasted Cancer Anorexia market size, Cancer Anorexia market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Cancer Anorexia therapaeutics market report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Cancer Anorexia Drugs Market.

Cancer Anorexia Treatment Market Report Insights

• Patient-based Cancer Anorexia Market Forecasting
• Therapeutic Approaches
• Cancer Anorexia Pipeline Analysis
• Cancer Anorexia Market Size and Trends
• Existing and future Cancer Anorexia Therapeutics Market Opportunity 

Cancer Anorexia Treatment Market Report Key Strengths

• 11 Years Cancer Anorexia Market Forecast
• The 7MM Coverage 
• Cancer Anorexia Epidemiology Segmentation
• Key Cross Competition 
• Conjoint analysis
• Drugs Uptake and Key Cancer Anorexia Market Forecast Assumptions

Cancer Anorexia Treatment Market Report Assessment

• Current Cancer Anorexia Treatment Market Practices
• Cancer Anorexia Unmet Needs
• Cancer Anorexia Pipeline Product Profiles
• Cancer Anorexia Therapeutics Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What is the historical and forecasted Cancer Anorexia patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What was the total Cancer Anorexia treatment market size, the Cancer Anorexia market size by therapies, Cancer Anorexia market share (%) distribution in 2023, and what would it look like in 2034? What are the contributing factors for this growth?
• What are the pricing variations among different geographies for approved and off-label therapies?
• What are the disease risks, burdens, and Cancer Anorexia Unmet Needs? What will be the growth opportunities across the 7MM concerning the patient population with Cancer Anorexia ?
• What are the current and emerging options for treating Cancer Anorexia? 
• How many companies are developing therapies to treat Cancer Anorexia?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to buy the Cancer Anorexia Market Report

• The Cancer Anorexia drugs market report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Cancer Anorexia treatment market.
• Insights on patient burden/disease Cancer Anorexia prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing Cancer Anorexia treatment market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying strong upcoming players in the Cancer Anorexia treatment market will help devise strategies to help get ahead of competitors.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Stay Updated with us for Recent Articles

• Limited Therapeutics Options and A Weak Pipeline: What Lies Ahead in the Cancer Anorexia Market?
• Cancer Anorexia Market: Infographics
• Cancer Anorexia Newsletter
• Latest DelveInsight Blogs